Alaunos Therapeutics (TCRT) Change in Receivables (2011 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Change in Receivables came in at -$3000.0 in Q1 2026, little changed YoY from -$3000.0 in Q1 2025, and down 200.0% on a QoQ basis from $3000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Change in Receivables (2011 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 16 years of Change in Receivables data on file, last reported at -$3000.0 in Q1 2026.
- Quarterly Change in Receivables changed 0.0% year-over-year to -$3000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2000.0 (down 300.0% YoY) and the FY2025 annual result came in at -$2000.0, down 150.0% from the prior year.
- Change in Receivables slipped to -$3000.0 in Q1 2026, from $3000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $2.9 million in Q3 2022 to a low of -$2.9 million in Q4 2022.
- A 5-year average of -$79357.1 and a median of -$2500.0 in 2025 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables sank 626.75% — and 2024, when it soared 400.0%.
- Tracing TCRT's Change in Receivables over 5 years: stood at -$2.9 million in 2022, then soared by 100.03% to $1000.0 in 2023, then soared by 400.0% to $5000.0 in 2024, then sank by 40.0% to $3000.0 in 2025, then slumped by 200.0% to -$3000.0 in 2026.
- The last three Change in Receivables figures came in at -$3000.0 (Q1 2026), $3000.0 (Q4 2025), and -$2000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,000.00 |
| Mar 31, 2026 | -3,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Mar 31, 2025 | -3,000.00 |
| Mar 31, 2025 | -3,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | -4,000.00 |
| Sep 30, 2024 | -4,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 4,000.00 |